Editorial Comment to Impact of low‐dose tadalafil on adverse events after low‐dose‐rate brachytherapy for prostate cancer: A bi‐center randomized open‐label trial

Abstract

ized prostate cancer: Seattle experience. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: 376–81. 2 Caffo O, Fellin G, Bolner A et al. Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2006; 66: 31–7. 3 Chen AB, D’Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J. Clin. Oncol. 2006; 24: 5298–304. 4 Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol. 2002; 41: 427–33. 5 Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002; 60: 650–5. 6 Tsumura H, Satoh T, Ishiyama H et al. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: e385–e392. 7 McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 2007; 177: 1401–7. 8 Curran M, Keating G. Tadalafil. Drugs 2003; 63: 2203–12. 9 Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J. Urol. 2002; 168: 1332–6. 10 Wang Y, Bao Y, Liu J, Duan L, Cui Y. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Low. Urin. Tract Symptoms. 2018; 10: 84–92. 11 Saito T, Minagawa T, Ogawa T, Ishizuka O. Efficacy of tadalafil against lower urinary tract symptoms after low-dose-rate brachytherapy in prostate cancer patients. J. Clin. Urol. 2019; 12: 223–7. 12 Kanai AJ, Zeidel ML, Lavelle JP et al. Manganese superoxide dismutase gene therapy protects against irradiation-induced cystitis. Am. J. Physiol. Renal. Physiol. 2002; 283: F1304–F1312. 13 Stewart FA, Lundbeck F, Oussoren Y, Luts A. Acute and late radiation damage in mouse bladder: a comparison of urination frequency and cystometry. Int. J. Radiat. Oncol. Biol. Phys. 1991; 21: 1211–9. 14 Vale JA, Bowsher WG, Liu K, Tomlinson A, Whitfield HN, Trott KR. Postirradiation bladder dysfunction: development of a rat model. Urol. Res. 1993; 21: 383–8. 15 Antonakopoulos GN, Hicks RM, Berry RJ. The subcellular basis of damage to the human urinary bladder induced by irradiation. J. Pathol. 1984; 143: 103–16. 16 Dorr W, Bentzen SM. Late functional response of mouse urinary bladder to fractionated X-irradiation. Int. J. Radiat. Biol. 1999; 75: 1307–15. 17 Imamura T, Shimamura M, Ogawa T et al. Biofabricated Structures Reconstruct Functional Urinary Bladders in Radiation-Injured Rat Bladders. Tissue Eng. Part A. 2018; 24: 1574–87. 18 Imamura T, Ogawa T, Minagawa T et al. Engineered bone marrow-derived cell sheets restore structure and function of radiation-injured rat urinary bladders. Tissue Eng. Part A. 2015; 21: 1600–10. 19 Imamura T, Ishizuka O, Lei Z et al. Bone marrow-derived cells implanted into radiation-injured urinary bladders reconstruct functional bladder tissues in rats. Tissue Eng. Part A. 2012; 18: 1698–709. 20 Morelli A, Sarchielli E, Comeglio P et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J. Sex Med. 2011; 8: 2746–60. 21 Amano T, Earle C, Imao T, Matsumoto Y, Kishikage T. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. Aging Male 2018; 21: 77–82. 22 Bertolotto M, Trincia E, Zappetti R, Bernich R, Savoca G, Cova MA. Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. Radiol. Med. 2009; 114: 1106–14. 23 Vignozzi L, Gacci M, Cellai I et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 2013; 73: 1391–402. 24 Roumeguere T, Zouaoui Boudjeltia K, Babar S et al. Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur. Urol. 2010; 57: 522–8. 25 Yu YD, Kang MH, Choi CI, Shin HS, Oh JJ, Park DS. Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on posttherapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer. World J. Urol. 2016; 34: 1269–74. 26 Ong WL, Hindson BR, Beaufort C, Pharoah P, Millar JL. Long-term erectile function following permanent seed brachytherapy treatment for localized prostate cancer. Radiother. Oncol. 2014; 112: 72–6. 27 Ferrer M, Suarez JF, Guedea F et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 421–32. 28 Pugh TJ, Mahmood U, Swanson DA et al. Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy 2015; 14: 160–5. 29 Ilic D, Hindson B, Duchesne G, Millar JL. A randomised, double-blind, placebocontrolled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. J. Med. Imaging Radiat. Oncol. 2013; 57: 81–8. 30 Pisansky TM, Pugh SL, Greenberg RE et al. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. JAMA 2014; 311: 1300–7.